Abstract
Purpose. All transplanted solid organs experience some degree of ischemia-reperfusion (I-R) injury. This I-R injury can contribute to graft dysfunction which stems in part from the acute phase response and a resultant host of cytokines. Recent evidence suggests that organs remote to the site of I-R injury can be affected by circulating cytokines originating from these I-R injuries. Since many of these acute phase cytokines inhibit hepatic cytochrome P-450 (CYP) enzymes, we chose to investigate whether extrahepatic I-R injuries could influence hepatic oxidative drug metabolism.
Methods. Fifteen dogs were divided into three surgical groups: (I) sham I-R; (II) bilateral normothermic renal I-R; and (III) normothermic intestinal I-R. Antipyrine (AP) was selected as a model substrate and administered intravenously at a dose of 10 mg/kg. AP serum concentrations were determined by HPLC and cytokine activity (IL-1, IL-6, and TNFα) was measured via bioassay. Serial AP clearance and serum cytokine concentrations were determined 3 days prior to and at 4 hr, 24 hr, 3 days and 7 days after surgery. Hematology and blood chemistries were monitored throughout the study period.
Results. AP clearance was significantly reduced in groups II and III at 4 and 24 hrs post-I-R injury, while AP binding and apparent volume of distribution were unaffected. Peak levels of TNF and IL-6 activity occurred at 1 and 4 hours, respectively. IL-1 activity was not detected in any group. AP clearance correlated strongly to circulating levels of IL-6 (r = −0.789, p = 0.0002).
Conclusions. Our findings indicate that extrahepatic I-R injury can affect hepatic oxidative drug metabolism and this effect is mediated in part by circulating cytokines.
Similar content being viewed by others
REFERENCES
P. C. Heinrich, J. V. Castell, and T. Andus. Biochem. J. 265:621–636 (1990).
T. D. Lindstrom, B. R. Hanssen, and A. M. Bendele. Mol. Pharmacol. 38:829–835 (1990).
J. Sonne, M. Dossing, S. Loft, and P. B. Andreasen. Clin. Pharmacol. Ther. 37:701–704 (1985).
L. K. Griffeth, G. M. Rosen, C. Tschanz, and E. J. Rauckman. Drug Metab. Dispos. 11:517–525 (1983).
J. S. Forsyth, T. A. Moreland, and G. W. Rylance. Br. J. Clin. Pharmac. 13:811–815 (1982).
E. A. Pullicino, F. Carli, S. Poole, B. Rafferty, S. Malik, and M. Elia. Lymphokine Res. 9:231–238 (1990).
B. Chindavijak, F. M. Belpaire, and M. G. Bogaert. J. Pharm. Pharmacol. 39:883–886 (1987).
Z. Abdel-Razzak, P. Loyer, A. Fautrel, J. Gautier, L. Corcos, B. Turlin, P. Beaune, and A. Guillouzo. Mol. Pharmacol. 44:707–715 (1993).
E. T. Morgan, K. B. Thomas, R. Swanson, T. Vales, J. Hwang, and K. Wright. Biochim. Biophys. Acta 1219:475–483 (1994).
G. Engel, U. Hofmann, H. Heidemann, J. Cosme, and M. Eichelbaum. Clin. Pharmacol. Ther. 59:613–623 (1996).
I. Velic, M. Metzler, H. G. Hege, and J. Weymann. J. Chromatog. B. 666:139–147 (1995).
F. F. Vickers, T. A. Bowman, B. H. Dvorchik, G. T. Passananti, D. M. Hughes, and E. S. Vesell. Drug Metab. Dispos. 17:160–165 (1989).
B. J. Gurley, S. Zermatten and D. Skelton. J. Pharm. Biomed. Anal. 12:1591–1595 (1994).
Wagner, J. G. J. Pharmacokinet. Biopharm. 4:443–467 (1976).
K. Yamashita, T. Fujinaga, M. Hagio, T. Miyamoto, Y. Izumisawa, and T. Kotani. J. Vet. Med. Sci. 56:103–107 (1994).
R. S. Poggetti, F. A. Moore, E. E. Moore, D. D. Bensard, B. O. Anderson, and A. Banerjee. Arch. Surg. 127:175–179 (1992).
J. W. Horton and D. J. White. J. Surg. Res. 55:282–289 (1993).
L. M. Colleti, S. L. Kunkel, A. Walz, M. D. Burdick, R. G. Kunkel, C. A. Wilke, and R. M. Strieter. J. Clin. Invest. 95:134–141 (1995).
S. I. Shedlofsky, B. C. Israel, C. J. McClain, D. B. Hill, and R. A. Blouin. J. Clin. Invest. 94:2209–2214 (1994).
D. R. LeMay, L. G. LeMay, M. J. Kluger, and L. G. D'Alecy. Am. J. Physiol. 259:R126–R132 (1990).
K. Yamashita, T. Fujinaga, T. Miyamoto, M. Hagio, Y. Izumisawa, and T. Kotani. J. Vet. Med. Sci. 56:487–492 (1994).
C. Pous, J. Giroud, C. Damais, D. Raichvarg, and L. Chauvelot-Moachon. Drug Metab. Dispos. 18:467–470 (1990).
M. Yasuhara, J. Fujiwara, S. Kitade, H. Katayama, K. Okumura, and R. Hori. J. Pharmacol. Exp. Ther. 235:513–520 (1985).
Y. Horie, R. Wolf, M. Miyasaka, D. C. Anderson, and D. N. Granger. Gastroenterol. 111:666–673 (1996).
J. G. Maessen, W. T. Hermens, M. Vork, and G. Koostra. Transplant. Proc. 21:2059–2060 (1989).
K. Eguchi, Y. Nishibe, T. Baba, and K. Ohno. Xenobiotica. 26:755–764 (1996).
H. Boxenbaum. J. Pharmacokinet. Biopharm. 8:165–176 (1980).
B. Gurley, S. Van Voorst, and R. Buice. Pharm. Res. 7:S-222 (1990).
Y. L. Chen, V. Le Vraux, A. Leneveu, F. Dreyfus, A. Stheneur, I. Florentin, M. De Sousa. J. P. Giroud, B. Flouvat, and L. Chauvelot-Moachon. Clin. Pharmacol. Ther. 55:649–660 (1994).
M. S. Karim, R. F. M. Wood, A. B. St. T. Dawnay, and P. A. Fulton. Transplantation. 49:500–502 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gurley, B.J., Barone, G.W., Yamashita, K. et al. Extrahepatic Ischemia-Reperfusion Injury Reduces Hepatic Oxidative Drug Metabolism as Determined by Serial Antipyrine Clearance. Pharm Res 14, 67–72 (1997). https://doi.org/10.1023/A:1012007517877
Issue Date:
DOI: https://doi.org/10.1023/A:1012007517877